Approach to the treatment-experienced patient.

被引:4
作者
Gallant J.E. [1 ]
机构
[1] Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, 21287, MD
关键词
Zidovudine; Resistance Testing; Nelfinavir; Abacavir; Atazanavir;
D O I
10.1007/s11904-005-0023-5
中图分类号
学科分类号
摘要
Failure of antiretroviral therapy can occur for a variety of reasons, but is often caused by or accompanied by drug resistance, which increases with continued time on nonsuppressive, failing regimens. Response to early virologic failure on an initial regimen may be associated with minimal or no resistance and can sometimes be managed simply by reinforcing adherence or by intensifying therapy. Resistance testing is an important tool for managing patients who are failing therapy; it should be used in most cases to guide selection of the next regimen. For patients with extensive treatment experience and drug resistance, there are a variety of approaches that have been suggested when fully suppressive options are not available. Clinicians caring for such patients must balance the benefit of slower progression associated with continued therapy against the risk of increasing drug resistance and loss of future treatment options.
引用
收藏
页码:83 / 89
页数:6
相关论文
共 138 条
[1]  
Deeks SG(1999)HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy AIDS 13 F35-F43
[2]  
Hecht FM(1999)Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study Lancet 353 863-868
[3]  
Swanson M(2001)The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study AIDS 15 201-209
[4]  
Ledergerber B(2001)Prevalence and predictive value of intermittent viremia with combination HIV therapy JAMA 286 171-179
[5]  
Egger M(2005)Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART JAMA 293 817-829
[6]  
Opravil M(2001)HIV-1 drug resistance profiles in children and adults with viral load of less than 50 copies/ml receiving combination therapy JAMA 286 196-207
[7]  
Mocroft A(2001)Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance J Acquir Immune Defic Syndr 28 105-113
[8]  
Phillips AN(2000)Antiretroviral resistance during successful therapy of HIV type 1 infection Proc Natl Acad Sci USA 97 10948-10953
[9]  
Miller V(1998)The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir AIDS 12 F9-14
[10]  
Havlir DV(1999)Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy AIDS 13 1337-1342